RevvityRVTY
NYSE · USA · Segment 5 of 8 in the Medicine, pharma & life science value chain: Life science tools
Newborn and genetic screening is the clinical end of the business; the rest supplies reagents and software to research laboratories.
Life science tools: Instruments, reagents and equipment for research, development and production.
Key metrics
Market cap
$13.1B
Price
$123.00
Today
−1.4%
Return YTD
+28.9%
Return 1Y
+39.1%
P/E
55.1
P/S
4.5
P/B
1.8
Data as of 2026-08-25 · updates daily after U.S. close
Theme exposure
In the value chain
Products & services
- Newborn & genetic screening
- Research reagents
- Laboratory software
Competitors
Risks
- Research budgets
- Post-divestiture integration
Supply chain
Supplies →
Same segment: Life science tools
Compare RVTY
See where Revvity sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →